How is high pulmonary artery pressure due to pulmonary veno‑occlusive disease differentiated from pulmonary artery pressure elevation caused by primary pulmonary arteriolar disease?

Differentiating PVOD from Primary Pulmonary Arteriolar Disease

High-resolution CT chest is the key diagnostic tool to differentiate pulmonary veno-occlusive disease (PVOD) from primary pulmonary arterial hypertension (PAH), with the combination of three specific CT findings—subpleural septal thickening, centrilobular ground-glass opacities, and mediastinal lymphadenopathy—being 100% specific for PVOD. 1

Diagnostic Algorithm

Clinical Presentation Clues

When evaluating elevated pulmonary artery pressures, certain clinical features should raise suspicion for PVOD rather than primary arteriolar disease:

• Physical examination findings unusual for PAH:

  • Digital clubbing 1, 2
  • Bi-basal crackles on lung auscultation 1, 2

• More severe gas exchange abnormalities:

  • Significantly lower diffusion capacity for carbon monoxide (DLCO) compared to other PAH forms 1, 3
  • More profound hypoxemia at rest 1, 4

• Demographics: Male predominance and higher tobacco exposure in PVOD 4

Hemodynamic Assessment

Critical caveat: Right heart catheterization cannot reliably distinguish PVOD from PAH because pulmonary capillary wedge pressure (PCWP) is almost invariably normal in PVOD 2. This occurs because the pathological obstruction affects small venules distal to where the wedge pressure is measured, not the larger pulmonary veins 2.

Both conditions present with:

• Mean PAP >25 mmHg
• PCWP ≤15 mmHg (precapillary pattern)
• Elevated pulmonary vascular resistance (PVR) >3 Wood units 5

High-Resolution CT Chest: The Definitive Differentiator

The diagnostic triad for PVOD on CT (100% specific when all three present): 1

1. Subpleural thickened septal lines (interlobular septal thickening)
2. Centrilobular ground-glass opacities (contrasting with panlobular distribution in idiopathic PAH)
3. Mediastinal lymphadenopathy

Additional supportive CT findings: 6

• Pleural effusion
• Normal-sized left atrium (distinguishes from left heart disease)
• Enlarged pulmonary arteries (common to both PVOD and PAH)

Ancillary Diagnostic Tests

Bronchoalveolar lavage: May reveal occult alveolar hemorrhage, supporting PVOD diagnosis 2, 4

Pulmonary function testing: Disproportionately reduced DLCO (often <45-55% predicted) relative to lung volumes 3, 4

Arterial blood gas: Lower PaO₂ at rest compared to PAH 4

Critical Management Implications

Why Differentiation Matters for Morbidity and Mortality

PVOD patients face life-threatening pulmonary edema when treated with PAH-specific vasodilators (prostanoids, endothelin receptor antagonists, phosphodiesterase-5 inhibitors), which can occur with any class of PAH drugs 1, 2, 7, 8. This represents a medical emergency and fundamentally different treatment paradigm.

Treatment Approach

• PVOD: Early referral to lung transplantation center as soon as diagnosis established 1, 2, 8
• Primary PAH: PAH-specific vasodilator therapy is first-line treatment

Prognosis: PVOD carries substantially worse prognosis with median survival <2 years without transplantation 9, 4, compared to better outcomes with modern PAH therapies for primary arteriolar disease.

Common Pitfalls to Avoid

1. Do NOT rely on wedge pressure to exclude PVOD—it will be normal despite venous pathology 2

2. Do NOT perform lung biopsy routinely—it carries substantial morbidity/mortality risk in pulmonary hypertension and is discouraged 3. Surgical biopsy should be reserved only when diagnosis cannot be established otherwise and is ideally performed at time of transplantation 6

3. Do NOT initiate PAH-specific therapy without first excluding PVOD via high-resolution CT in patients with precapillary pulmonary hypertension 2, 7

4. Recognize that absence of pulmonary edema during vasodilator therapy does not exclude PVOD—some patients may tolerate therapy initially without developing edema 10